SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED

Highlights SciClone Pharmaceuticals (Holdings) Limited

Equities

6600

KYG4271B1023

Delayed Hong Kong S.E. Other stock markets 11:59:12 2024-06-03 pm EDT			5-day change	1st Jan Change
18.52 ^HKD	+0.33%		+0.54%	+33.05%

May. 16	Sciclone Pharmaceuticals Limited Announces Change of Address of Principal Place of Business in Hong Kong	CI
Apr. 18	Sciclone Pharmaceuticals to Dispatch Privatization Documents by May 31	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Sciclone Pharmaceuticals to Dispatch Privatization Documents by May 31	Apr. 18	MT
SciClone Pharmaceuticals Logs 31% Increase in 2023 Profit	Apr. 01	MT
SciClone Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
GL China Opportunities Fund IV L.P. and GL China Opportunities Fund IV L.P., managed by GL Capital Group and GL Capital Management GP L.P. agreed to acquire 66.69% stake in SciClone Pharmaceuticals Limited for HKD 7.9 billion.	Mar. 27	CI
SciClone Pharmaceuticals Limited Announces Phase III Clinical Trial of Vaborem® Completed Subject Enrollment in China	Jan. 31	CI
Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer	Nov. 07	CI
SciClone Pharmaceuticals Limited and Menarini Establish License and Collaboration Agreement for Orserdu in China	Nov. 06	CI
SciClone Pharmaceuticals' Profit Jumps 18.4% in H1	23-08-18	MT
SciClone Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-17	CI
SciClone Pharmaceuticals Limited Announces First Subject Dosed in Phase III Clinical Trial of Vaborem in China	23-07-04	CI
SciClone Pharmaceuticals Limited Announces Commercial Launch of DANYELZA in China	23-07-02	CI
SciClone Pharmaceuticals Limited commences an Equity Buyback Plan for 61,829,507 shares, representing 10% of its issued share capital, under the authorization approved on May 25, 2023.	23-06-06	CI
SciClone Pharmaceuticals Limited Approves a Final Dividend for the Year Ended December 31, 2022	23-05-25	CI
SciClone Pharmaceuticals Limited's Equity Buyback announced on May 20, 2022, has expired.	23-05-24	CI
Sciclone Pharmaceuticals Limited Declares Final Dividend for the Year Ended December 31, 2022, Payable on 28 June 2023	23-03-30	CI
SciClone Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Sciclone Pharmaceuticals Limited Announces Nmpa Approval of Ind Application for Vaborem	23-03-19	CI
SciClone Pharmaceuticals Limited Announces Acceptance of Investigational New Drug Application for Vaborem by Center for Drug Evaluation of the China National Medical Products Administration	22-12-27	CI
SciClone Pharmaceuticals Limited Announces NMPA Approval of Biologics License Application of Danyelza for Patients with Relapsed or Refractory High-Risk Neuroblastoma in China	22-12-08	CI
EpicentRx Announces Start of Dosing in China for Global Phase 3 Clinical Trial REPLATINUM (NCT05566041) with Partner SciClone Pharmaceuticals	22-10-06	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights SciClone Pharmaceuticals (Holdings) Limited

Equities

6600

KYG4271B1023

Highlights

Filters